Dr. Cliff Hudis: Multi-Targeted Therapy Is Extending Non-Chemotherapy Options in Advanced Breast Cancer
Dr. Cliff Hudis: Multi-Targeted Therapy Is Extending Non-Chemotherapy Options in Advanced Breast Cancer
Interview by L Scott Zoeller
20110004
2011 Jan 4
Top Stories of 2010
Dr. Cliff Hudis: Multi-Targeted Therapy Is Extending Non-Chemotherapy Options in Advanced Breast Cancer
Top Stories of 2010. 2011 Jan 4, Interview by L Scott Zoeller
Abstract
Dr. Clifford A. Hudis is Chief, Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer, New York, NY. OncologySTAT: In your view, which development in advanced breast cancer research that occurred in 2010 could have the most impact on oncology?Dr. Hudis: I think that the big advances in breast cancer research are in targeted therapy, primarily those drugs that are targeting HER2, but also including, obviously, the Poly (ADP-ribose) polymerase (PARP) inhibitors and, potentially, others. This...
Meet Our Experts
Meet our Advisory and Editorial Boards comprised of physician editors and world-renowned experts.
